Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180)

Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293) . This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 0.98 μg/mL using SARS-CoV-2 Inhibitor Screening Kit.Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

Product Specifications

Background

It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

CAS Number

9007-83-4

Host

HEK293

Origin Species

Human

Target

Spike RBD

Conjugation

Unconjugated

Tag

Human IgG1 | Human Kappa

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.

Purity

0.95

Bioactivity

Serial dilutions of Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180) (Cat. No. SPD-M180) were added into SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3): Biotinylated Human ACE2, His,Avitag (Cat. No. AC2-H82E6) binding reactions. The half maximal inhibitory concentration (IC50) is 0.98269 μg/mL (Routinely tested).